<p>Avalon Capital Management 在最近向 SEC 提交的文件中表示，該公司在第二季度增持了 Danaher Co.（NYSE:DHR - 免費報告）的持股，增幅達 250.5%。該基金在本季度購入額外的 2,718 股後，持有這家企業的 3,803 股股票。Avalon Capital Management 在最近一次向 SEC 提交的文件中，持有的 Danaher 股票價值為$950,000。</p>
<ul>
<li>Danaher 股票會在 2024 年創下新高嗎？</li>
</ul>
<p>其他許多大型投資者最近也調整了他們對該企業的持股。Leonard Rickey Investment Advisors P.L.L.C.在第二季度購入了 Danaher 股票的新頭寸，價值約$204,000。Bay Colony Advisory Group Inc d b a Bay Colony Advisors 在第二季度增持了 Danaher 的持股，增幅為 6.5%。Bay Colony Advisory Group Inc d b a Bay Colony Advisors 現在擁有 6,750 股這家企業的股票，價值$1,686,000，上季度購入額外的 412 股。Arcus Capital Partners LLC 在第二季度增持了 Danaher 的持股，增幅為 12.0%。Arcus Capital Partners LLC 現在擁有 3,135 股這家企業的股票，價值$783,000，上季度購入額外的 335 股。&amp;PARTNERS 在第二季度購入了 Danaher 的新股份，價值約$1,257,000。最後，Geneos Wealth Management Inc.在第二季度增持了 Danaher 的持股，增幅為 3.9%。Geneos Wealth Management Inc.現在擁有 14,826 股這家企業的股票，價值$3,704,000，上季度購入額外的 554 股。目前，該股有 79.05% 的股份由機構投資者持有。</p>
<h2>Danaher 股價上漲 0.6%</h2>
<p>DHR 週五上漲$1.65，報價$269.48。公司交易了 1,367,720 股股票，相比其平均交易量 2,820,898 股有所減少。該股的 50 天移動平均價格為$258.42，200 天移動平均價格為$254.18。Danaher Co.的 52 周最低價為$182.09，最高價為$281.70。該公司的市值為$1996 億美元，市盈率為 45.39，PEG 比率為 4.62，貝塔係數為 0.83。該公司的資產負債比為 0.33，流動比率為 1.43，速動比率為 1.04。</p>
<ul>
<li>三大藍籌股 - 現在最值得購買的藍籌股</li>
</ul>
<p>Danaher（NYSE:DHR - 獲取免費報告）最近公佈了截至 7 月 23 日星期二的季度收益數據。該企業報告本季度每股收益為$1.72，超過了分析師預期的$1.57，超出$0.15。Danaher 的淨利潤率為 16.94%，淨資產收益率為 11.06%。該季度，該公司的營收為 57.4 億美元，超過了 55.9 億美元的共識預期。與去年同期相比，該公司的營收同比下降了 2.9%。賣方分析師平均預計，Danaher Co.本財年的每股收益將達到 7.59 美元。</p>
<h2>分析師設定新的價格目標</h2>
<p>DHR 已成為多家研究分析師報告的熱門話題。Stifel Nicolaus 將 Danaher 的目標股價從 235.00 美元上調至 250.00 美元，並在 7 月 24 日星期三的研究報告中給予該公司 “持有” 評級。StockNews.com 在 6 月 25 日星期二的報告中，將 Danaher 的股票評級從 “買入” 調降至 “持有”。加拿大皇家銀行在 7 月 24 日星期三的報告中，將 Danaher 的目標股價從 297.00 美元上調至 300.00 美元，並給予該股 “表現優異” 評級。巴克萊將 Danaher 的目標股價從 270.00 美元上調至 285.00 美元，並給予該股 “等權重” 評級。最後，Robert W. Baird 將 Danaher 的目標股價從 271.00 美元上調至 278.00 美元，並給予該股 “表現優異” 評級。六位分析師對該股的評級為持有，十二位對該公司的股票發出買入評級。根據 MarketBeat 的數據，該公司目前的平均評級為 “中等買入”，共識價格目標為 276.88 美元。</p>
<ul>
<li>醫療股票 - 最值得購買的醫療科技股票</li>
</ul>
<p><strong>獲取我們關於 Danaher 的最新報告</strong></p>
<h2>內部人士押注</h2>
<p>在其他 Danaher 的消息中，首席財務官 Matthew Mcgrew 於 8 月 1 日星期四出售了 16,172 股公司股票。這些股票的平均價格為 279.84 美元，總價值為 4,525,572.48 美元。在完成交易後，首席財務官現在直接持有公司股票 29,407 股，價值 8,229,254.88 美元。該交易已在與證券交易委員會的法律文件中披露，可以通過此超鏈接訪問。另外，高級副總裁 Brian W. Ellis 於 7 月 25 日星期四以 275.16 美元的平均價格出售了公司的 9,600 股股票。此次交易總價值為 2,641,536.00 美元。交易完成後，這位高級副總裁現在直接持有公司股票 20,230 股，價值 5,566,486.80 美元。關於此次交易的披露可以在此處找到。內部人士在過去 90 天內出售了價值 10,786,944 美元的 38,707 股公司股票。公司內部人士持有公司股份的比例為 11.10%。</p>
<h2>Danaher 公司簡介（免費報告）</h2>
<p>丹納赫公司在全球設計、製造和銷售專業、醫療、工業和商業產品和服務。生物技術部門提供生物工藝技術、耗材和服務，推動、加速和整合治療藥物的開發和生產；細胞系和細胞培養培養基開發服務；用於製造的細胞培養基、工藝液體和緩衝液、色譜樹脂、過濾技術、無菌灌裝；一次性硬件和耗材以及服務，如全套生產套件的設計和安裝；實驗室過濾、分離和純化；實驗室規模的蛋白純化和分析工具；試劑、膜和服務；以及醫療保健過濾解決方案。</p>
<h2>參考資料</h2>
<ul>
<li>五隻我們比丹納赫更喜歡的股票</li>
<li>關於標記計算器</li>
<li>Lumen：上個月表現優異，但仍有警示信號</li>
<li>高飛者：2022 年 3 月的 3 只天然氣股票</li>
<li>百度強勁季度證明邁克爾·伯裏的明智選擇</li>
<li>經紀排名在股票選擇中的重要性</li>
<li>Intuit 擊敗第四季度盈利：人工智能、股息和增長策略</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURIUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURIUg"/></p>
<p><em>這則即時新聞警報是由市場數據和 narrative science 技術生成的，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
<p>→ 44 年華爾街老兵：&#34;不可逆轉的破壞即將降臨美國&#34; (來自 InvestorPlace)(廣告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTgx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTgx"/></p>
<h2>現在是否值得投資$1,000 美元購買丹納赫？</h2>
<p>在考慮投資丹納赫之前，您需要聽到這個消息。</p>
<p>MarketBeat 追蹤華爾街評級最高、表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴客户現在購買，而丹納赫不在名單上。</p>
<p>儘管目前分析師對丹納赫的評級為&#34;中等買入&#34;，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

丹納赫

<p>Avalon Capital Management 在第二季度增持了丹納赫公司（NYSE：DHR）的持股，增加了 250.5%，購入了 2,718 股，總持股量達到 3,803 股。該股上漲了 0.6%，報價為$[current price]。其他投資包括 Leonard Rickey 投資顧問和 Bay Colony 諮詢集團。分析師設定了$[target price] 的共識目標價，平均評級為 “中等買入”。丹納赫的第二季度收益超過了預期，報告的每股收益為$0.72。首席財務官 Matthew Mcgrew 最近出售了 16,172 股股票，價值約$[sale price]</p>

<p>Avalon Capital Management lifted its holdings in Danaher Co. (NYSE:DHR - Free Report) by 250.5% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 3,803 shares of the conglomerate's stock after buying an additional 2,718 shares during the quarter. Avalon Capital Management's holdings in Danaher were worth $950,000 as of its most recent filing with the SEC.</p>
<ul>
<li>Will Danaher stock hit new highs in 2024?</li>
</ul>
<div class="lb-trans"><p>Avalon Capital Management 在最近向 SEC 提交的文件中表示，該公司在第二季度增持了 Danaher Co.（NYSE:DHR - 免費報告）的持股，增幅達 250.5%。該基金在本季度購入額外的 2,718 股後，持有這家企業的 3,803 股股票。Avalon Capital Management 在最近一次向 SEC 提交的文件中，持有的 Danaher 股票價值為$950,000。</p>
<ul>
<li>Danaher 股票會在 2024 年創下新高嗎？</li>
</ul>
</div><p>A number of other large investors also recently modified their holdings of the business. Leonard Rickey Investment Advisors P.L.L.C. bought a new position in shares of Danaher in the 2nd quarter worth about $204,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors lifted its position in Danaher by 6.5% in the 2nd quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 6,750 shares of the conglomerate's stock valued at $1,686,000 after purchasing an additional 412 shares during the last quarter. Arcus Capital Partners LLC lifted its position in Danaher by 12.0% in the 2nd quarter. Arcus Capital Partners LLC now owns 3,135 shares of the conglomerate's stock valued at $783,000 after purchasing an additional 335 shares during the last quarter. &amp;PARTNERS bought a new stake in Danaher in the 2nd quarter valued at about $1,257,000. Finally, Geneos Wealth Management Inc. lifted its position in Danaher by 3.9% in the 2nd quarter. Geneos Wealth Management Inc. now owns 14,826 shares of the conglomerate's stock valued at $3,704,000 after purchasing an additional 554 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他許多大型投資者最近也調整了他們對該企業的持股。Leonard Rickey Investment Advisors P.L.L.C.在第二季度購入了 Danaher 股票的新頭寸，價值約$204,000。Bay Colony Advisory Group Inc d b a Bay Colony Advisors 在第二季度增持了 Danaher 的持股，增幅為 6.5%。Bay Colony Advisory Group Inc d b a Bay Colony Advisors 現在擁有 6,750 股這家企業的股票，價值$1,686,000，上季度購入額外的 412 股。Arcus Capital Partners LLC 在第二季度增持了 Danaher 的持股，增幅為 12.0%。Arcus Capital Partners LLC 現在擁有 3,135 股這家企業的股票，價值$783,000，上季度購入額外的 335 股。&amp;PARTNERS 在第二季度購入了 Danaher 的新股份，價值約$1,257,000。最後，Geneos Wealth Management Inc.在第二季度增持了 Danaher 的持股，增幅為 3.9%。Geneos Wealth Management Inc.現在擁有 14,826 股這家企業的股票，價值$3,704,000，上季度購入額外的 554 股。目前，該股有 79.05% 的股份由機構投資者持有。</p>
</div><h2>Danaher Stock Up 0.6 %</h2>
<div class="lb-trans"><h2>Danaher 股價上漲 0.6%</h2>
</div><p>DHR traded up $1.65 on Friday, reaching $269.48. 1,367,720 shares of the company traded hands, compared to its average volume of 2,820,898. The stock's 50 day moving average price is $258.42 and its 200-day moving average price is $254.18. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70. The company has a market cap of $199.60 billion, a price-to-earnings ratio of 45.39, a PEG ratio of 4.62 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04.</p>
<ul>
<li>The 3 Best Blue-Chip Stocks to Buy Now</li>
</ul>
<div class="lb-trans"><p>DHR 週五上漲$1.65，報價$269.48。公司交易了 1,367,720 股股票，相比其平均交易量 2,820,898 股有所減少。該股的 50 天移動平均價格為$258.42，200 天移動平均價格為$254.18。Danaher Co.的 52 周最低價為$182.09，最高價為$281.70。該公司的市值為$1996 億美元，市盈率為 45.39，PEG 比率為 4.62，貝塔係數為 0.83。該公司的資產負債比為 0.33，流動比率為 1.43，速動比率為 1.04。</p>
<ul>
<li>三大藍籌股 - 現在最值得購買的藍籌股</li>
</ul>
</div><p>Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating analysts' consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the previous year, the firm posted $2.05 earnings per share. The firm's revenue was down 2.9% on a year-over-year basis. On average, sell-side analysts expect that Danaher Co. will post 7.59 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Danaher（NYSE:DHR - 獲取免費報告）最近公佈了截至 7 月 23 日星期二的季度收益數據。該企業報告本季度每股收益為$1.72，超過了分析師預期的$1.57，超出$0.15。Danaher 的淨利潤率為 16.94%，淨資產收益率為 11.06%。該季度，該公司的營收為 57.4 億美元，超過了 55.9 億美元的共識預期。與去年同期相比，該公司的營收同比下降了 2.9%。賣方分析師平均預計，Danaher Co.本財年的每股收益將達到 7.59 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
</div><p>DHR has been the topic of several research analyst reports. Stifel Nicolaus raised their target price on shares of Danaher from $235.00 to $250.00 and gave the company a &#34;hold&#34; rating in a research note on Wednesday, July 24th. StockNews.com downgraded shares of Danaher from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, June 25th. Royal Bank of Canada boosted their target price on shares of Danaher from $297.00 to $300.00 and gave the stock an &#34;outperform&#34; rating in a report on Wednesday, July 24th. Barclays boosted their target price on shares of Danaher from $270.00 to $285.00 and gave the stock an &#34;equal weight&#34; rating in a report on Wednesday, July 24th. Finally, Robert W. Baird boosted their target price on shares of Danaher from $271.00 to $278.00 and gave the stock an &#34;outperform&#34; rating in a report on Wednesday, July 24th. Six analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $276.88.</p>
<ul>
<li>Medical Stocks - Best Medical Technology Stocks to Buy</li>
</ul>
<div class="lb-trans"><p>DHR 已成為多家研究分析師報告的熱門話題。Stifel Nicolaus 將 Danaher 的目標股價從 235.00 美元上調至 250.00 美元，並在 7 月 24 日星期三的研究報告中給予該公司 “持有” 評級。StockNews.com 在 6 月 25 日星期二的報告中，將 Danaher 的股票評級從 “買入” 調降至 “持有”。加拿大皇家銀行在 7 月 24 日星期三的報告中，將 Danaher 的目標股價從 297.00 美元上調至 300.00 美元，並給予該股 “表現優異” 評級。巴克萊將 Danaher 的目標股價從 270.00 美元上調至 285.00 美元，並給予該股 “等權重” 評級。最後，Robert W. Baird 將 Danaher 的目標股價從 271.00 美元上調至 278.00 美元，並給予該股 “表現優異” 評級。六位分析師對該股的評級為持有，十二位對該公司的股票發出買入評級。根據 MarketBeat 的數據，該公司目前的平均評級為 “中等買入”，共識價格目標為 276.88 美元。</p>
<ul>
<li>醫療股票 - 最值得購買的醫療科技股票</li>
</ul>
</div><p><strong>Get Our Latest Report on Danaher</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Danaher 的最新報告</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士押注</h2>
</div><p>In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of the business's stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares of the company's stock, valued at $8,229,254.88. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of the business's stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares of the company's stock, valued at $8,229,254.88. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Also, SVP Brian W. Ellis sold 9,600 shares of the company's stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares of the company's stock, valued at $5,566,486.80. The disclosure for this sale can be found here. Insiders sold 38,707 shares of company stock valued at $10,786,944 over the last ninety days. Corporate insiders own 11.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Danaher 的消息中，首席財務官 Matthew Mcgrew 於 8 月 1 日星期四出售了 16,172 股公司股票。這些股票的平均價格為 279.84 美元，總價值為 4,525,572.48 美元。在完成交易後，首席財務官現在直接持有公司股票 29,407 股，價值 8,229,254.88 美元。該交易已在與證券交易委員會的法律文件中披露，可以通過此超鏈接訪問。另外，高級副總裁 Brian W. Ellis 於 7 月 25 日星期四以 275.16 美元的平均價格出售了公司的 9,600 股股票。此次交易總價值為 2,641,536.00 美元。交易完成後，這位高級副總裁現在直接持有公司股票 20,230 股，價值 5,566,486.80 美元。關於此次交易的披露可以在此處找到。內部人士在過去 90 天內出售了價值 10,786,944 美元的 38,707 股公司股票。公司內部人士持有公司股份的比例為 11.10%。</p>
</div><h2>Danaher Company Profile (Free Report)</h2>
<div class="lb-trans"><h2>Danaher 公司簡介（免費報告）</h2>
</div><p>Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.</p>
<div class="lb-trans"><p>丹納赫公司在全球設計、製造和銷售專業、醫療、工業和商業產品和服務。生物技術部門提供生物工藝技術、耗材和服務，推動、加速和整合治療藥物的開發和生產；細胞系和細胞培養培養基開發服務；用於製造的細胞培養基、工藝液體和緩衝液、色譜樹脂、過濾技術、無菌灌裝；一次性硬件和耗材以及服務，如全套生產套件的設計和安裝；實驗室過濾、分離和純化；實驗室規模的蛋白純化和分析工具；試劑、膜和服務；以及醫療保健過濾解決方案。</p>
</div><h2>See Also</h2>
<ul>
<li>Five stocks we like better than Danaher</li>
<li>About the Markup Calculator</li>
<li>Lumen: Among Top Performers Last Month, Still Has Warning Signs</li>
<li>High Flyers: 3 Natural Gas Stocks for March 2022</li>
<li>Baidu's Strong Quarter Proves a Smart Pick for Michael Burry</li>
<li>The Significance of Brokerage Rankings in Stock Selection</li>
<li>Intuit Beats Q4 Earnings: AI, Dividends, and a Growth Strategy</li>
</ul>
<div class="lb-trans"><h2>參考資料</h2>
<ul>
<li>五隻我們比丹納赫更喜歡的股票</li>
<li>關於標記計算器</li>
<li>Lumen：上個月表現優異，但仍有警示信號</li>
<li>高飛者：2022 年 3 月的 3 只天然氣股票</li>
<li>百度強勁季度證明邁克爾·伯裏的明智選擇</li>
<li>經紀排名在股票選擇中的重要性</li>
<li>Intuit 擊敗第四季度盈利：人工智能、股息和增長策略</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURIUg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=DHR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由市場數據和 narrative science 技術生成的，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><p>→ 44-year Wall Street Vet: “Irreversible destruction is coming to America” (From InvestorPlace)(Ad)</p>
<div class="lb-trans"><p>→ 44 年華爾街老兵：&#34;不可逆轉的破壞即將降臨美國&#34; (來自 InvestorPlace)(廣告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTgx" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9181&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Danaher right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資$1,000 美元購買丹納赫？</h2>
</div><p>Before you consider Danaher, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資丹納赫之前，您需要聽到這個消息。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街評級最高、表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴客户現在購買，而丹納赫不在名單上。</p>
</div><p>While Danaher currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管目前分析師對丹納赫的評級為&#34;中等買入&#34;，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Avalon 資本管理公司提升了丹納赫公司（紐約證券交易所代碼：DHR）的股票持有量